McMullen, Suzanne
Hess, Lisa M.
Kim, Edward S.
Levy, Benjamin
Mohamed, Mohamed
Waterhouse, David
Wozniak, Antoinette
Goring, Sarah
Müller, Kerstin http://orcid.org/0000-0003-3315-4674
Muehlenbein, Catherine
Aggarwal, Himani
Zhu, Yajun
Oton, Ana B.
Ersek, Jennifer L.
Winfree, Katherine B.
Funding for this research was provided by:
Eli Lilly and Company
Article History
First Online: 21 August 2018
Compliance with Ethical Standards
:
: The data that support the findings of this study are not available publicly; however, future collaborative research using the data may be possible upon reasonable request from the authors.
: This study was funded by Eli Lilly and Company.
: Suzanne McMullen and Kerstin Müeller are employees of ICON plc, a contract research organization (CRO) that was contracted by Eli Lilly and Company (Lilly) to conduct this study. Sarah Goring was an employee of ICON at the time the study was conducted, and is currently working for ICON as an independent contractor. Catherine Muehlenbein, Himani Aggarwal, Ana B. Oton, and Katherine B. Winfree are employees of Lilly and own stock in the company. Lisa M. Hess and Yajun Zhu are Lilly employees. Edward S. Kim has received consulting fees and honoraria as well as support for travel to meetings from AstraZeneca, Celgene, Boehringer Ingelheim, and Lilly. Mohamed Mohamed has received honoraria for speaker engagements from Eli Lilly, BMS, Merck, Boehringer Ingelheim, AstraZeneca, and Genentech. David Waterhouse has served on or moderated advisory boards for AbbVie, Amgen, and AstraZeneca, has had paid consulting engagements with BMS and Clinical Trial Services (CTI), and has been paid as a speaker by Lilly, BMS, Celgene, and Genenech/Roche. Antoinette Wozniak has received research funding from Boehringer Ingelheim, as well as honoraria/consulting fees from Boehringer Ingelheim, AstraZeneca, Takeda, Coherus Biosciences, Hospira, HUYA Bioscience, and Beyond Spring Biopharmaceuticals. Benjamin Levy has received research funding from Celgene and Boehringer Ingelheim, and consulting fees from Eli Lilly, AstraZeneca, Celgene, Pfizer, Merck, Genentech, and Takeda. Jennifer L. Ersek declares no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible ethics committee and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. This study has been approved by the relevant ethics boards (physician survey: Western Institutional Review Board [WIRB]; chart review: WIRB, Marshfield Clinic Research Foundation Institutional Review Board [IRB], Chesapeake IRB, IRB of Beth Israel Medical Center, University of Southern California Health Sciences IRB; Qualitative interviews: Cone Health IRB; patient survey: WIRB, Chesapeake IRB, Cone Health IRB).
: SM, LH, BL, MM, SG, KM, CM, HA, EZ, AO, and KW were involved in designing and planning the study and developing study materials. SM, KM, and SG were responsible for operationalization of the study. EK, BL, MM, DW, and JE collected data at their respective clinics. SG conducted the statistical analysis. SM and KM wrote the manuscript; all authors reviewed, provided critical input, and approved the final version.